Senseonics develops long-term implantable continuous glucose monitoring (CGM) systems, most notably the Eversense 365, which uses a small sensor placed entirely under the skin to measure glucose levels continuously for up to 365 days. The sensor works with a rechargeable external smart transmitter and a smartphone app that delivers real-time readings and alerts. This approach targets people with diabetes who prefer fewer sensor insertions compared with shorter-duration wearable CGM products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 6.7 | — | -14.5 | — |
| Q3 2025 | 8.1 | — | -19.5 | — |
| Q4 2025 | 14.3 | — | -20.8 | — |
| Q1 2026 | 11.7 | — | -32.3 | — |
| Q2 2026 | 14.5 | 117.8% | -36.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Fossil Group, Inc. (FOSL), Assembly Biosciences, Inc. (ASMB), DiaMedica Therapeutics Inc. (DMAC), AgomAb Therapeutics NV (AGMB), Citi Trends, Inc. (CTRN), Value Line, Inc. (VALU)